Alzheimer's disease: a review on the current trends of the effective diagnosis and therapeutics

被引:7
作者
Abdul Manap, Aimi Syamima [1 ]
Almadodi, Reema [2 ]
Sultana, Shirin [2 ]
Sebastian, Maheishinii Grace [2 ]
Kavani, Kenil Sureshbhai [2 ]
Lyenouq, Vanessa Elle [2 ]
Shankar, Aravind [2 ]
机构
[1] King Faisal Univ, Coll Vet Med, Dept Biomed Sci, Al Hasa, Saudi Arabia
[2] MAHSA Univ, Fac Pharm & Biomed Sci, Selangor, Malaysia
来源
FRONTIERS IN AGING NEUROSCIENCE | 2024年 / 16卷
关键词
Alzheimer's disease; AD; dementia; diagnosis; treatment; clinical trial; SCALE-COGNITIVE SUBSCALE; AMYLOID-BETA; CEREBROSPINAL-FLUID; NEUROPSYCHIATRIC SYMPTOMS; AXONAL-TRANSPORT; TAU-PROTEIN; DEMENTIA; BRAIN; MILD; BIOMARKER;
D O I
10.3389/fnagi.2024.1429211
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The most prevalent cause of dementia is Alzheimer's disease. Cognitive decline and accelerating memory loss characterize it. Alzheimer's disease advances sequentially, starting with preclinical stages, followed by mild cognitive and/or behavioral impairment, and ultimately leading to Alzheimer's disease dementia. In recent years, healthcare providers have been advised to make an earlier diagnosis of Alzheimer's, prior to individuals developing Alzheimer's disease dementia. Regrettably, the identification of early-stage Alzheimer's disease in clinical settings can be arduous due to the tendency of patients and healthcare providers to disregard symptoms as typical signs of aging. Therefore, accurate and prompt diagnosis of Alzheimer's disease is essential in order to facilitate the development of disease-modifying and secondary preventive therapies prior to the onset of symptoms. There has been a notable shift in the goal of the diagnosis process, transitioning from merely confirming the presence of symptomatic AD to recognizing the illness in its early, asymptomatic phases. Understanding the evolution of disease-modifying therapies and putting effective diagnostic and therapeutic management into practice requires an understanding of this concept. The outcomes of this study will enhance in-depth knowledge of the current status of Alzheimer's disease's diagnosis and treatment, justifying the necessity for the quest for potential novel biomarkers that can contribute to determining the stage of the disease, particularly in its earliest stages. Interestingly, latest clinical trial status on pharmacological agents, the nonpharmacological treatments such as behavior modification, exercise, and cognitive training as well as alternative approach on phytochemicals as neuroprotective agents have been covered in detailed.
引用
收藏
页数:31
相关论文
共 232 条
  • [1] A Mental Workout, 2023, Alzheimers disease and dementia
  • [2] Abushakra S, 2016, J Prev Alzheimers Dis, V3, P219, DOI 10.14283/jpad.2016.115
  • [3] Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer's Disease
    Akincioglu, Hulya
    Gulcin, Ilhami
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2020, 20 (08) : 703 - 715
  • [4] Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias
    Alcolea, Daniel
    Delaby, Constance
    Munoz, Laia
    Torres, Soraya
    Estelles, Teresa
    Zhu, Nuole
    Barroeta, Isabel
    Carmona-Iragui, Maria
    Illan-Gala, Ignacio
    Santos-Santos, Miguel Angel
    Altuna, Miren
    Sala, Isabel
    Sanchez-Saudinos, M. Belen
    Videla, Laura
    Valldeneu, Silvia
    Subirana, Andrea
    Pegueroles, Jordi
    Hirtz, Christophe
    Vialaret, Jerome
    Lehmann, Sylvain
    Karikari, Thomas K.
    Ashton, Nicholas J.
    Blennow, Kaj
    Zetterberg, Henrik
    Belbin, Olivia
    Blesa, Rafael
    Clarimon, Jordi
    Fortea, Juan
    Lleo, Alberto
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021, 92 (11) : 1206 - 1214
  • [5] Hyperphosphorylation of Tau Associates With Changes in Its Function Beyond Microtubule Stability
    Alonso, Alejandra D.
    Cohen, Leah S.
    Corbo, Christopher
    Morozova, Viktoriya
    ElIdrissi, Abdeslem
    Phillips, Greg
    Kleiman, Frida E.
    [J]. FRONTIERS IN CELLULAR NEUROSCIENCE, 2018, 12
  • [6] Applying the ATN scheme in a memory clinic population The ABIDE project
    Altomare, Daniele
    de Wilde, Arno
    Ossenkoppele, Rik
    Pelkmans, Wiesje
    Bouwman, Femke
    Groot, Colin
    van Maurik, Ingrid
    Zwan, Marissa
    Yaqub, Maqsood
    Barkhof, Frederik
    van Berckel, Bart N.
    Teunissen, Charlotte E.
    Frisoni, Giovanni B.
    Scheltens, Philip
    van der Flier, Wiesje M.
    [J]. NEUROLOGY, 2019, 93 (17) : E1635 - E1646
  • [7] Accelerated Brain Volume Loss Caused by Anti-β-Amyloid Drugs A Systematic Review and Meta-analysis
    Alves, Francesca
    Kalinowski, Pawel
    Ayton, Scott
    [J]. NEUROLOGY, 2023, 100 (20) : E2114 - E2124
  • [8] Alzheimers Dementia Resource Center, 2023, FAQ - Alzheimers and dementia
  • [9] 2020 Alzheimer's disease facts and figures
    不详
    [J]. ALZHEIMERS & DEMENTIA, 2020, 16 (03) : 391 - 460
  • [10] [Anonymous], 2023, Alzheimer's disease fact sheet